Research in laboratory animals has shown that 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) destroys serotonergic axons in the brain at certain doses. Serotonin is known to take part in the regulation of mood in humans. Many researchers have hypothesized that if recreational ecstasy use destroys serotonergic axons, then a corresponding decline in the mood of ecstasy users should be seen. The purpose of the present study was to look at the relationship between recreational ecstasy use and depression as measured by the Beck Depression Inventory-II. No signi.cant differences were found between Beck Depression Inventory-II scores of heavy ecstasy users and ecstasynaive college students. No signi.cant relationships were found between Beck Depression Inventory-II scores and any of the measures of ecstasy use. Most ecstasy users who had been diagnosed with a psychiatric disorder reported that being diagnosed preceded their use of ecstasy.
Al-Musawi , Nu'man M (2001) Psychometric properties of the Beck Depression Inventory-II with university students in Bahrain . J Pers Assess77: 568–579
2.
Baron P , Hanna J (1990) Egocentrism and depressive symptomatology in young adults . Soc Behav Pers Int J18: 279–285
3.
Beck A T , Steer R A , Brown G K (1996) Beck Depression Inventory-II manual. The Psychological Corporation, San Antonio, TX
4.
Beck A T , Steer R A , Garbin M G (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation . Clin Psychol Rev8: 77–100 .
5.
Buchert R , Thomasius R , Wilke F , Petersen K , Nebeling B , Obrocki J , Schulze O , Schmidt U , Clausen M (2004) A voxel-based PET investigation of the long-term effects of ‘ecstasy’ consumption on brain serotonin transporters . Am J Psychiatry161: 1181–1189
6.
Buchert R , Thomasius R , Nebeling B , Petersen K , Obrocki J , Jenicke L , Wilke F , Wartberg L , Zapletalova P , Clausen M (2003) Long-term effects of ‘ecstasy’ use on serotonin transporters of the brain investigated by PET . J Nucl Med44: 375–384
7.
Cole J C , Bailey M , Sumnall H R , Wagstaff G F , King L A (2002) The content of ecstasy tablets: implications for the study of their long-term effects . Addiction97: 1531–1536
8.
Commins D L , Vosmer G , Virus R M , Woolverton W L , Schuster C R , Seiden, L S (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain . J Pharmacol Exp Ther241: 338–345
9.
Daumann J , Pelz S , Becker S , Tuchtenhagen F , Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use . Hum Psychopharmacol Clin Exp16: 627–633
10.
Daumann J , Hensen G , Thimm B , Rezk M , Till B , Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation . Psychopharmacology173: 398–404
11.
de Almeida S P , Silva M T A (2005) Characteristics of ecstasy users in Sao Paulo, Brazil . Subst Use Misuse40: 395–404
12.
de Win M M L , Reneman L , Reitsma J B , den Heeten G J , Booij J , van den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users: the influence of long-term abstention, dose, and gender . Psychopharmacology173: 376–382
13.
Dobson K S , Breiter H J (1983) Cognitive assessment of depression: reliability and validity of three measures . J Abnorm Psychol92: 107–109
14.
Dozois D J A (2003) The psychometric characteristics of the Hamilton Depression Inventory . J Pers Assess80: 31–40
15.
Dughiero G , Schifano F , Forza G (2001) Personality dimensions and psychopathological profiles of ecstasy users . Hum Psychopharmacol Clin Exp16: 635–639
16.
Falck R S , Wang J , Carlson R G , Siegal H A (2006) Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio . Addict Behav31: 90–101
17.
Gotlib I H (1984) Depression and general psychopathology in university students . J Abnorm Psychol93: 19–30
18.
Greer G , Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting . J Psychoactive Drugs18: 319–327
19.
Grinspoon L , Bakalar J B (1986) Can drugs be used to enhance the psychotherapeutic process?Am J Psychother40: 393–404
20.
Halpern J H , Pope H G , Sherwood A R , Barry S , Hudson J I , Yougelun-Todd D (2004) Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs . Drug Alcohol Depend75: 135–147
21.
Lieb R , Schuetz C G , Pfister H , von Sydow K , Wittchen H (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation . Drug Alcohol Depend68: 195–207
22.
Lightfoot S L , Oliver J M (1985) The Beck Inventory: psychometric properties in university students . J Pers Assess49: 434–436
23.
MacInnes N , Handley S L , Harding G F A (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms . J Psychopharmacol15: 181–186
24.
McCann U D , Ricaurte G A (2001) Caveat emptor: editors beware . Neuropsychopharmacology24: 333–334
25.
McCann U D , Szabo Z , Scheffel U , Dannals R F , Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA (‘ecstasy’) on brain serotonin neurons in human beings . Lancet352: 1433–1437
26.
McCann U D , Szabo Z , Secklin E , Rosenblatt P , Mathews W B , Ravert H T , Dannals R F , Ricaurte G A (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB . Neuropsychopharmacology30: 1741–1750
27.
McCardle K , Luebbers S , Carter J D , Croft R J , Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood . Psychopharmacology173: 434–439
28.
Milani R M , Parrott A C , Turner J J D , Fox H C (2004) Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users . Addict Behav29: 965–971
29.
Morgan M J , McFie L , Fleetwood L H , Robinson J A (2002) ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?Psychopharmacology159: 294–303
30.
National Institute of Mental Health (2002) Medications (Publication No. 02–3929). Retrieved 27 September 2004, from http://www.nimh.nih.gov/publicat/medicate.cfm
31.
O'Hearn E , Battaglia G , De Souza E B , Kuhar M J , Molliver M E (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity . J Neurosci8: 2788–2803
32.
Parrott A C (2004) Is ecstasy MDMA? a review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity . Psychopharmacology173: 234–241
33.
Parrott A C , Sisk E , Turner J J D (2000) Psychobiological problems in heavy ecstasy (MDMA) polydrug users . Drug Alcohol Depend60: 105–110
34.
Parrott A C , Milani R M , Parmar R , Turner J J D (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems . Psychopharmacology159: 77–82
35.
Reneman L , Lavalaye J , Schmand B , de Wolff F A , van den Brink W , den Heeten G J (2001a) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ecstasy): preliminary findings . Arch Gen Psychiatry58: 901–906
36.
Reneman L , Booij J , de Bruin K , Reitsma J B , de Wolff F A , Gunning W B , den Heeten G J , van den Brink W (2001b) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons . Lancet358: 1864–1869
37.
Ricaurte G A , DeLanney L E , Irwin I , Langston J W (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration . Brain Res446: 165–168
38.
Ricaurte G A , Martello A L , Katz J L , Martello M B (1992) Lasting effects of (δ/ +)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations . J Pharmacol Exp Ther261: 616–622
39.
Rizley R (1978) Depression and distortion in the attribution of causality . J Abnorm Psychol87: 32–48
40.
Robbins P R , Tanck R H (1984) The Beck Depression Inventory and selfreports of behavior over a ten-day period . J Pers Assess48: 42–45
41.
Robinson L A , Berman J S , Neimeyer RA (1990) Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research . Psychol Bull108: 30–49
42.
Roiser J P , Sahakian B J (2004) Relationship between ecstasy use and depression: a study controlling for polydrug use . Psychopharmacology173: 411–417
43.
Semple D M , Ebmeier K P , Glabus M F , O'Carroll R E , Johnstone E C (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (ecstasy) users . Br J Psychiatry175: 63–69
44.
Shipley W C (1940) A self-administering scale for measuring intellectual impairment and deterioration . J Psychol9: 371–377
45.
Steer R A , Clark D A (1997) Psychometric characteristics of the Beck Depression Inventory-II with college students . Meas Eval Couns Dev30: 128–136
46.
Storch E A , Roberti J W , Roth D A (2004) Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second Edition in a sample of college students . Depress Anxiety19: 187–189
47.
Sumnall H R , Cole J C (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis . J Psychopharmacol19: 84–92
48.
Thomasius R , Petersen K , Buchert R , Andresen B , Zapletalova P , Wartberg L , Nebeling B , Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users . Psychopharmacology167: 85–96
49.
Verheyden S L , Henry J A , Curran H V (2003) Acute, sub-acute and longterm subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users . Hum Psychopharmacol Clin Exp18: 507–517
50.
Verkes R J , Gijsman H J , Pieters M S M , Schoemaker R C , de Visser S , Kuijpers M , Pennings E J M , de Bruin D , Van de Wijngaart G , Van Gerven J M A , Cohen A F (2001) Cognitive performance and serotonergic function in users of ecstasy . Psychopharmacology153: 196–202
51.
Vollenweider F X , Jones R T , Baggott M J (2001) Caveat emptor: editors beware . Neuropsychopharmacology24: 461–463
52.
Vollenweider F X , Gamma A , Liechti M , Huber T (1999) Is a single dose of MDMA harmless?Neuropsychopharmacology21: 598–600
53.
von Geusau N A , Stalenhoef P , Huizinga M , Snel J , Ridderinkhof K R (2004) Impaired executive function in male MDMA (‘ecstasy’) users . Psychopharmacology175: 331–341
54.
Weiss J L , Schell R E (1991) Estimating WAIS-R IQ from the Shipley Institute of Living Scale: a replication . J Clin Psychol47: 558–562
55.
Whisman M A , Perez J E (2000) Factor structure of the Beck Depression Inventory-Second Edition (BDI-II) in a student sample . J Clin Psychol56: 545–551
56.
Wilson M A , Ricaurte G A , Molliver M E (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine . Neuroscience28: 121–137
57.
Zachary R A (1991) Revised manual for the Shipley Institute of Living Scale. Western Psychological Services, Los Angeles
58.
Zachary R A , Crumpton E , Spiegel D E (1985) Estimating WAIS-R IQ from the Shipley Institute of Living Scale . J Clin Psychol41: 532–540
